Trump’s Order on Psychedelic Drugs Sparks Support Among Veterans

President Donald Trump has signed an executive order that permits research into psychedelic drugs for treating PTSD and other mental health issues. This decision has generated positive reactions, especially among military veterans. Notable supporters include former Energy Secretary Rick Perry and retired Navy SEAL Marcus Luttrell, who both advocate for these innovative treatments. FDA Commissioner Dr. Marty Makary commented on the promising potential for such therapies.

Meanwhile, a separate legal dispute has emerged involving former Netflix executive Kevin Baillie. According to The New York Post, Baillie has filed a lawsuit against Netflix. The suit claims he was terminated after revealing his use of medically supervised ketamine treatment for depression. This disclosure happened during a workplace event where employees were encouraged to share personal experiences.

Baillie, who served as vice president and head of creative at the visual effects division Eyeline Studios, reportedly earned around $1.1 million annually. His lawsuit alleges Netflix withheld severance pay following his dismissal. The complaint states that Baillie spoke about his treatment at a Netflix retreat in Northern California in January. He underwent ketamine therapy for clinical depression after his mother’s death, with the treatment administered under medical supervision.

A Netflix investigator reportedly questioned Baillie, suggesting the treatment might involve recreational drug use. Beyond this, the investigation cited Baillie’s language and alcohol consumption as factors in his dismissal. His previous performance review addressed his language, advising him to reduce profanity but not cease entirely.

The lawsuit highlights Netflix’s workplace culture, which values vulnerability and openness among employees. Managers at Netflix apply a “keeper test” when deciding whether to retain staff, promoting candid feedback and performance evaluation.

In his legal action, Baillie is seeking a jury trial and compensation for lost wages, emotional distress, and punitive damages. He is known for his work on the “Pirates of the Caribbean” and “Harry Potter” franchises. Netflix has yet to publicly respond to his claims. Efforts to contact Baillie and Netflix for comment were unsuccessful at the time of reporting.

Ketamine is a Schedule III controlled substance approved as an anesthetic and also prescribed off-label for depression. The FDA has approved Spravato, a ketamine-derived nasal spray, for treatment-resistant depression under medical supervision.